Jazz Pharma Plc JAZZ

$235.67 +2.66 (1.14%)

Valuation

Market cap
15,125,844,000
Revenue TTM
$4,267,590,000
Net income TTM
$-356,150,000
PE ratio
10.02
Forward PE
10.72
Profit margin
-8.35%
Debt to equity
0.91

Trading

Volume
636,600
Avg volume
902,806
Day's range
$231.70 – $237.77
Shares out
64,915,000
Stochastic %K
46%
Beta
0.37
Analysts
Strong Sell
Price target
$293.86

Price

Company profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the trea...

Show more

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Industry
Biotechnology
Sector
Healthcare
Phone
353 1 634 7800
Website
https://www.jazzpharma.com
Address
Waterloo Exchange, Fifth Floor Waterloo Road Dublin 4, Dublin, Ireland

Latest news

Stocktwits

Makingmillions192 Sep 30, 2:41 PM
$LEXX Lexaria re-engaged market focus on hypertension by highlighting blood pressure and cardiovascular benefits alongside GLP-1 weight-loss outcomes in their December 30, 2025 secondary endpoint study (GLP-1-H24-4), while explicitly securing patent coverage for hypertension in late 2025 and 2026. Prospective Partners for Lexaria’s Hypertension Platform - Alnylam: Integrates oral delivery with RNA-based pipelines. -The George Medicines: Adds non-synthetic tech to multi-mechanism combo pills. - Idorsia / Mineralys: Gains a Phase 1b/2-ready asset for resistant blood pressure without early R&D costs. - Sun Pharma / Dr. Reddy’s: Licenses pre-cleared FDA IND assets for emerging markets. - Takeda / Daiichi Sankyo: Extends product lifecycles for legacy heart franchises. - Jazz Pharma (GW): Expands beyond Epidiolex directly into cardiovascular indications using proven blood-pressure data. Maybe this is why the 5.9m was needed… time will tell… $JAZZ $SUNPHARMA.NSE $ALNY
0 replies
Makingmillions192 Sep 28, 5:11 PM
$LEXX Based on recent comments from about transferring R&D costs to external partners one can only assume they are positioned for an out-licensing deal. Probably with a mid-tier regional partner. If Lexaria signs a regional out-licensing deal (e.g., licensing DehydraTECH GLP-1 rights in Asia to a mid-tier pharma like PegBio or Sun Pharma), the financial reset instantly eliminates the sub-cash discount and establishes a commercial floor. Valuation Reset Breakdown Upfront Cash Influx: A typical regional mid-tier deal brings $10M–$25M in upfront cash. Immediate Enterprise Value Re-Rate: Net cash jumps from ~$7.9M ($4.60/share) to $18M–$33M ($10.50–$19.20/share). The EV flips instantly from negative to positive as the market applies a baseline platform multiplier. Royalties: The headline deal includes $50M–$150M+ in clinical/commercial milestones plus tier-based royalties (5%–12%) on regional sales, all while the partner absorbs local R&D/trial costs. $TEVA $JAZZ $SUNPHARMA.NSE
0 replies
Merlintrader Sep 25, 6:45 PM
Narcolepsy after the orexin approval: $ALKS, $AXSM, $JAZZ and $TAK https://www.merlintrader.com/narcolepsy-orexin-alks-axsm-jazz-tak/
0 replies
Quantumup Sep 24, 1:20 PM
H.C. Wainwright reiterated $PRAX Buy-$1201 and said -- As part of our "Biopharma Deep Dive" call series, we recently hosted Marcio Souza, President and Chief Executive Officer of Praxis Precision Medicines. $RAPP $JAZZ SAGE DRUG UCBJY ESAIY OVID XENE Here's what H.C. Wainwright went on to say: https://x.com/Quantumup1/status/2103112067632758871?s=20
1 replies
NeverFadeTheOracle Sep 24, 12:35 PM
$JAZZ 337 Buy Goldman & Sachs
0 replies
investpapaya Sep 22, 9:36 PM
$NBIX $JAZZ $BIIB If you were to go ALL IN on one of these stocks ( for long term), which one would you choose?
0 replies
investpapaya Sep 22, 9:33 PM
$JAZZ is an undervalued stock, with strong growth and catalysts in 2026-2027.
0 replies
LibertarianTreehugger Sep 22, 7:42 PM
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition? https://www.fool.com/investing/2026/09/18/should-you-buy-jazz-pharmaceuticals-stock-after-it/ $JAZZ
0 replies